Shield Therapeutics Management
Management criteria checks 2/4
Shield Therapeutics' CEO is Greg Madison, appointed in Jun 2021, has a tenure of 2.83 years. total yearly compensation is $819.61K, comprised of 59.9% salary and 40.1% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth £26.98K. The average tenure of the management team and the board of directors is 2.8 years and 3.4 years respectively.
Key information
Greg Madison
Chief executive officer
US$819.6k
Total compensation
| CEO salary percentage | 59.9% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | US$820k | US$491k | -US$49m |
| Sep 30 2022 | n/a | n/a | -US$36m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$585k | US$295k | -US$27m |
Compensation vs Market: Greg's total compensation ($USD819.61K) is above average for companies of similar size in the UK market ($USD345.35K).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
CEO
Greg Madison (56 yo)
2.8yrs
Tenure
US$819,613
Compensation
Mr. Gregory P. Madison, also known as Greg, was the Chief Executive Officer and President of Keryx Biopharmaceuticals Inc. since 2015 until April 27, 2018. He served as Chief Executive Officer at Chief Exe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | US$819.61k | 0.24% $ 27.0k | |
| Co-Founder & Non Executive Director | 16.3yrs | US$54.40k | 1.49% $ 166.0k | |
| Chief Financial Officer | less than a year | no data | no data | |
| General Counsel & Company Secretary | 6.6yrs | no data | no data | |
| Group HR Director | no data | no data | no data | |
| Head of Pharmacovigilance & Medical Information | no data | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Senior Director of People & Culture | no data | no data | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: STX's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | US$819.61k | 0.24% $ 27.0k | |
| Co-Founder & Non Executive Director | 3.8yrs | US$54.40k | 1.49% $ 166.0k | |
| Independent Non-Executive Director | 8.2yrs | US$38.68k | 0.023% $ 2.5k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 2.9yrs | US$54.40k | 0.035% $ 3.9k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 2.9yrs | US$61.65k | 0.0013% $ 142.6 | |
| Independent Non Executive Chairman | 5.8yrs | US$124.51k | 0.70% $ 78.4k | |
| Notable Scientific Advisory Board | no data | no data | no data |
3.4yrs
Average Tenure
57yo
Average Age
Experienced Board: STX's board of directors are considered experienced (3.4 years average tenure).